Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications
Xiao-dan Xia, Zhongsheng Peng, Hongmei Gu, et al.
Frontiers in Cardiovascular Medicine (2021) Vol. 8
Open Access | Times Cited: 65

Showing 1-25 of 65 citing articles:

Targeting PCSK9 to tackle cardiovascular disease
Sandra Hummelgaard, Joachim Vilstrup, Camilla Gustafsen, et al.
Pharmacology & Therapeutics (2023) Vol. 249, pp. 108480-108480
Open Access | Times Cited: 55
PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint Inhibitors to Reduce Cardiovascular Events: New Frontiers in Cardioncology
Vincenzo Quagliariello, Irma Bisceglia, Massimiliano Berretta, et al.
Cancers (2023) Vol. 15, Iss. 5, pp. 1397-1397
Open Access | Times Cited: 27
Single-cell transcriptomic analyses reveal distinct immune cell contributions to epithelial barrier dysfunction in checkpoint inhibitor colitis
Molly Thomas, Kamil Slowikowski, Kasidet Manakongtreecheep, et al.
Nature Medicine (2024) Vol. 30, Iss. 5, pp. 1349-1362
Closed Access | Times Cited: 16
A promising therapy for fatty liver disease: PCSK9 inhibitors
Lizhu Han, Liuyun Wu, Qinan Yin, et al.
Phytomedicine (2024) Vol. 128, pp. 155505-155505
Closed Access | Times Cited: 9
High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany
Umidakhon Makhmudova, Ulrike Schatz, Nikolaos Perakakis, et al.
Clinical Research in Cardiology (2023) Vol. 112, Iss. 11, pp. 1639-1649
Open Access | Times Cited: 22
Immune Regulation of the Liver Through the PCSK9/CD36 Pathway During Heart Transplant Rejection
Xi Zhang, Heng Xu, Jizhang Yu, et al.
Circulation (2023) Vol. 148, Iss. 4, pp. 336-353
Open Access | Times Cited: 17
Surf4, cargo trafficking, lipid metabolism, and therapeutic implications
Yishi Shen, Hongmei Gu, Shucun Qin, et al.
Journal of Molecular Cell Biology (2022) Vol. 14, Iss. 9
Open Access | Times Cited: 28
PCSK9 inhibitor inclisiran for treating atherosclerosis via regulation of endothelial cell pyroptosis
Ni Kong, Qin Xu, Wei Cui, et al.
Annals of Translational Medicine (2022) Vol. 10, Iss. 22, pp. 1205-1205
Open Access | Times Cited: 23
PCSK9, A Promising Novel Target for Age-Related Cardiovascular Dysfunction
Csaba Mátyás, Eszter Trojnár, Suxian Zhao, et al.
JACC Basic to Translational Science (2023) Vol. 8, Iss. 10, pp. 1334-1353
Open Access | Times Cited: 15
High fat diet and PCSK9 knockout modulates lipid profile of the liver and changes the expression of lipid homeostasis related genes
Krisztína Németh, Blanka Tóth, Farkas Sarnyai, et al.
Nutrition & Metabolism (2023) Vol. 20, Iss. 1
Open Access | Times Cited: 14
PCSK9 inhibitors as safer therapeutics for atherosclerotic cardiovascular disease (ASCVD): Pharmacophore design and molecular dynamics analysis
Ibrahim Oluwatobi Kehinde, Oluwole B. Akawa, Adeniyi T. Adewumi, et al.
Journal of Cellular Biochemistry (2024) Vol. 125, Iss. 7
Closed Access | Times Cited: 6
Association between Immune Checkpoint Inhibitors and Atherosclerotic Cardiovascular Disease Risk: Another Brick in the Wall
Linda Piras, Michela Zuccanti, Paola Russo, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2502-2502
Open Access | Times Cited: 5
Inhibition of PCSK9: a promising enhancer for anti-PD-1/PD-L1 immunotherapy
Shengbo Sun, Jingxin Ma, Tingting Zuo, et al.
Research (2024) Vol. 7
Open Access | Times Cited: 5
The role of hepatic Surf4 in lipoprotein metabolism and the development of atherosclerosis in apoE−/− mice
Yishi Shen, Hongmei Gu, Lei Zhai, et al.
Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids (2022) Vol. 1867, Iss. 10, pp. 159196-159196
Closed Access | Times Cited: 22
The Pleiotropic Effects of Lipid-Modifying Interventions: Exploring Traditional and Emerging Hypolipidemic Therapies
Dimitris Kounatidis, Nikolaοs Tentolouris, Natalia G. Vallianou, et al.
Metabolites (2024) Vol. 14, Iss. 7, pp. 388-388
Open Access | Times Cited: 4
Inclisiran—A Revolutionary Addition to a Cholesterol-Lowering Therapy
Adrianna Dec, Aleksandra Niemiec, Eliza Wojciechowska, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6858-6858
Open Access | Times Cited: 11
Lowering LDL cholesterol by PCSK9 inhibition: a new era of gene silencing, RNA, and alternative therapies
Mitali Paryani, Nikita Gupta, Sanjay K. Jain, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
PCSK9 with a gain of function D374Y mutation aggravates atherosclerosis by inhibiting PPARα expression
Yan Cui, Xi Chen, Tuoluonayi Mijiti, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Impact of PCSK9 gene polymorphism on atorvastatin efficacy in Iraqi hyperlipidemic patients
Khalid Mohammed, Mazin H. Ouda, Suzanne Jubair
Gene Reports (2025), pp. 102181-102181
Closed Access
Programmable mRNA therapeutics for controlled epigenomic modulation of single and multiplexed gene expression in diverse diseases
Colm P. O’Donnell, Jeremiah D. Farelli, Houda Belaghzal, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
A Systematic Review with Network Meta-analysis on Atherosclerosis Vaccine Based on Nonhuman Primate Model
Asyraf Muzaffar, Ayers Gilberth Ivano Kalaij, Fajar Fakri, et al.
Journal of Preventive Diagnostic and Treatment Strategies in Medicine (2025) Vol. 4, Iss. 1, pp. 18-25
Closed Access
Regulation of Platelet Function by HDL
M. Pilard, Sara Babran, C. Martel
Arteriosclerosis Thrombosis and Vascular Biology (2025)
Closed Access
Genetic Variants, Bioactive Compounds, and PCSK9 Inhibitors in Hyper-LDL-Cholesterolemia: A GWAS and In Silico Study on Cardiovascular Disease Risk
Meiling Liu, Junyu Zhou, Sunmin Park
Nutrients (2025) Vol. 17, Iss. 9, pp. 1411-1411
Open Access
Complex, cell‐type‐specific role of EEPD1: Bridging TNF‐α, inflammation and apoptosis in endothelial cells
Rong Li, Chong Zhang, Gaohui Zhu, et al.
Clinical and Translational Discovery (2025) Vol. 5, Iss. 3
Open Access
Structural dynamics of LDL receptor interactions with E498A and R499G variants of PCSK9
Nur Alya Amirah Azhar, Yung-An Chua, Hapizah Nawawi, et al.
Journal of Molecular Modeling (2025) Vol. 31, Iss. 6
Open Access
Page 1 - Next Page

Scroll to top